Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avantis U.S. Equity ETF (NY:AVUS)

102.50 +0.66 (+0.65%)
Streaming Delayed Price Updated: 12:53 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Avantis U.S. Equity ETF

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps
While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory... 
Via Stocktwits
Topics Death
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results
Organon said that the mid-stage study evaluating its OG-6219 in endometriosis-related pain did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to... 
Via Stocktwits
Rivian Stock Slides After Sales Slump In Q2, Despite $1B Equity Boost From Volkswagen
Rivian said production was limited during the quarter in preparation for model year 2026 vehicles, which are expected to launch later in July. 
Via Stocktwits
Ford US Sales Surge 14% In Q2 Despite EV Slump: Pickup Trucks, SUVs Drive Demand
The company’s truck sales jumped 11% in the three months through the end of June to 342,761 units, thanks to increased demand for the F-series, Ranger, and Maverick. 
Via Stocktwits
Topics Electric Vehicles
Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial
The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate. 
Via Stocktwits
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
AT&T Gains FCC Approval to Replace Copper Lines With Wireless Tech
AT&T (T) gets FCC approval to replace old copper home phone lines with wireless technology, expanding 5G network and fiber coverage for growth. 
Via Benzinga
3 ETFs to Buy Now for High Returns and Low Risk
These three ETFs to buy now try have delivered solid risk-adjusted returns to investors over the long haul. 
Via InvestorPlace
ETF Battles: Which Value Equity ETF Is The Winner?
An audience-requested quadruple header between 4 value equity ETFs from American Century, Charles Schwab, State Street Global Advisors, and Vanguard. 
Via Talk Markets
ETF Battles: Which Broad Stock Market ETF Is Best?
An audience-requested contest between broad stock market ETFs from American Century, State Street Global Advisors, and Vanguard. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.